Six-year experience with a triple drug protocol in renal transplantation: analysis of risk factors.
Pallardó
L M
LM
Department of Nephrology, Hospital Universitario La Fe, Valencia, Spain.
Sánchez
P
P
Sánchez
J
J
García
J
J
Orero
E
E
Beneyto
I
I
Cruz
J M
JM
D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D015999:Multivariate Analysis; D011183:Postoperative Complications / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D016016:Proportional Hazards Models; D012307:Risk Factors; D015996:Survival Rate
D006680:HLA Antigens; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone